NCT03690141 - An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2020

Conditions

Castrate-resistant Prostate Cancer (CRPC)

Interventions

DRUG

eFT508

This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.

Trial Locations (10)

17604

Lancaster Urology, Lancaster

21205

Kimmel Center at Johns Hopkins, Baltimore

29572

Carolina Urologic Research Center, Myrtle Beach

45212

The Urology Group, Cincinnati

48201

Karmanos Cancer Institute, Detroit

60611

Northwestern University, Chicago

63110

Washington University, St Louis

89109

University of Washington, Seattle

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

06510

Yale Cancer Center, New Haven